PMID: 11902499Mar 21, 2002Paper

Trastuzumab: hopes and realities

The Lancet Oncology
B Leyland-Jones

Abstract

Despite improvements in care of patients with breast cancer, up to half develop refractory or resistant disease. There is therefore a need for new, modified anticancer therapies with greater effectiveness, tolerability to patients, and tumour specificity. Trastuzumab (Herceptin) is the first clinically available oncogene-targeted therapeutic agent for treatment of solid tumours. Clinical trials in patients positive for HER2 (human epidermal-growth-factor receptor 2) show that trastuzumab is effective and well tolerated; as a single-agent second-line or third-line treatment, the drug produced durable tumour responses. First-line trastuzumab in combination with chemotherapy, particularly paclitaxel, significantly improved time to disease progression, duration of response, and time to treatment failure. Combination therapy resulted in a 25% improvement in overall survival compared with chemotherapy alone. Patients with HER2 gene amplification, high overexpression of HER2 (3+ on immunohisto-chemistry), or both features, obtained the greatest clinical benefit. Trastuzumab is the first monoclonal antibody with efficacy in breast cancer and the first gene-product-targeted therapy to produce a significant survival advantage in this dis...Continue Reading

References

Apr 11, 1992·Lancet·J M Bliss, J R Yarnold
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Oct 29, 1992·The New England Journal of Medicine·M J McKay, A O Langlands
May 11, 1991·Journal of Clinical Immunology·H M ShepardA Ullrich
Jan 1, 1993·Breast Cancer Research and Treatment·C C BenzC K Osborne
Sep 1, 1993·Cancer Immunology, Immunotherapy : CII·G D LewisH M Shepard
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Jun 17, 1999·International Journal of Cancer. Journal International Du Cancer·F FarabegoliM Derenzini
Feb 5, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·R E JimenezD W Visscher
Jul 29, 2000·Cancer Treatment Reviews·M C GreenG N Hortobagyi
Mar 27, 2001·Journal of Clinical Pathology·I O EllisP B Lee
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Baselga, J Albanell

❮ Previous
Next ❯

Citations

May 9, 2003·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Junichi Kurebayashi
May 5, 2004·Gynécologie, obstétrique & fertilité·P Beuzeboc
Apr 23, 2004·Trends in Molecular Medicine·Emanuel F Petricoin, Lance A Liotta
Dec 17, 2002·Current Opinion in Biotechnology·Mohit TrikhaMarian T Nakada
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Linda E Bröker, Giuseppe Giaccone
Aug 12, 2003·Breast Cancer Research and Treatment·Gian Paolo DagradaSilvana Pilotti
Dec 5, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Uta ReicheltGuido Sauter
Mar 16, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Coya TapiaGuido Sauter
Jul 29, 2005·Nature Genetics·Howard L McLeod, Sharon Marsh
Sep 5, 2002·Nature Reviews. Drug Discovery·Emanuel F PetricoinLance A Liotta
Nov 30, 2005·The Pharmacogenomics Journal·A WoelderinkE Rodriguez-Cerezo
Jan 18, 2012·The Pharmacogenomics Journal·D SanoudouD Pectasides
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Oct 13, 2006·Human Gene Therapy·Margaret A LiuGunilla B Karlsson Hedestam
Jun 27, 2006·Journal of Immunotherapy·Bernard J ScallonMarian T Nakada
May 22, 2007·Breast Cancer Research : BCR·Coya TapiaLukas Bubendorf
Aug 24, 2012·PloS One·Keith R MillerEdward J Collins
Feb 7, 2013·Journal of Cancer·Gabriel TinocoAlberto J Montero
Nov 26, 2002·Immunological Reviews·Hans-Georg RammenseeStefan Stevanović
Nov 21, 2007·Cancer Investigation·Jeffrey A NemethRobert A Beckman
Jun 19, 2013·Critical Reviews in Oncology/hematology·Girolamo RanieriRaffaele Luigi Sciorsci
Sep 17, 2008·Translational Oncology·Tiziana NegriSilvana Pilotti
Jul 4, 2007·The Breast : Official Journal of the European Society of Mastology·Evanthia KostopoulouGeorge Koukoulis
Aug 13, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kenji KonoSadahito Aoshima
Jun 30, 2007·Journal of Internal Medicine·S PhogatG B Karlsson Hedestam
Apr 10, 2010·Expert Review of Proteomics·Kant M MatsudaStephen M Hewitt
Jan 20, 2006·Critical Reviews in Biotechnology·Anu Kalia, R P Gupta
Mar 15, 2005·FEBS Letters·Silvia BenvenutiAlberto Bardelli
Jul 30, 2016·Frontiers in Oncology·Natalie J Serkova, S Gail Eckhardt
Aug 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chi-Chen LinMing-Derg Lai

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J Baselga
Breast Cancer : the Journal of the Japanese Breast Cancer Society
Toshiaki Saeki
© 2022 Meta ULC. All rights reserved